Navigation Links
Sosei Signs Definitive Distribution Agreement With ASKA for Commercialisation of SOH-075 (NorLevo(R))
Date:11/2/2009

TOKYO, November 2 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announced that Sosei Co., Ltd., its wholly owned Japanese subsidiary, has entered into a definitive distribution agreement with ASKA Pharmaceuticals Co., Ltd. ("ASKA", TSE First Section Index: 4514) for the commercialisation of the emergency contraceptive pill SOH-075 (NorLevo(R)).

NorLevo(R) is an oral emergency contraceptive "morning after pill" which is used to prevent unwanted pregnancy after unprotected intercourse. NorLevo(R) contains only levonorgestrel as an active ingredient. The dosing is started within 72 hours after unprotected sexual intercourse. NorLevo(R) was first launched in Europe in 1999 and is currently approved in some 60 countries, the product being both safe and effective as an oral emergency contraceptive for post-coital use.

Sosei have acquired the exclusive distribution rights to the product in Japan from HRA Pharma. The NDA application for SOH-075 was submitted in Japan in September 2009.

The agreement is based on the terms of a binding letter of agreement that was announced on 22 October 2008. According to this agreement, Sosei is responsible for development and registration and ASKA for sales and marketing.

In accordance with the agreement, Sosei will receive upfront, milestone payments as well as a margin on product sales to ASKA.

Notes for Editors:

About Sosei

Sosei is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical markets by acquiring compounds from, and bringing compounds into, Japan. For further information about Sosei, please visit http://www.sosei.com.

SOURCE Sosei Group Corporation


'/>"/>
SOURCE Sosei Group Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Sosei Announces Completion of Phase III Trial for NorLevo(R)
2. Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting
3. Sosei Confirms the Safety of SD118 in Two Phase I Trials
4. Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237
5. Sosei Assigns AD 923 Assets to Pharmasol
6. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
7. StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations
8. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
9. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
10. New AVEENO(R) Eczema Care Product Line Offers Breakthrough Formulas to Help Manage the Signs and Symptoms of Eczema
11. ALS Therapy Development Institute Signs Collaboration Agreement with the Allen Institute for Brain Science
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... 2017  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a ... commercialization of innovative therapies for the treatment of ... Agency (EMA) has notified the company that the ... Application (MAA) has passed validation, and that the ... MAA for ARX-04 (known as DSUVIA™ in the ...
(Date:3/28/2017)... MARLBOROUGH, Mass. , March 28, 2017 /PRNewswire/ ... RNAi company developing innovative therapeutics that address significant ... granted a patent from the Japan Patent Office ... targeting connective tissue growth factor (CTGF) for the ... not limited to skin fibrosis and proliferative retinopathy ...
(Date:3/28/2017)... 28, 2017 The global ... 8.0 billion by 2025, according to a new study ... infectious diseases and cancer is expected to upsurge the ... over the coming years. In addition, higher number of ... allogenic stem cell therapy, due to adverse effects caused ...
Breaking Medicine Technology:
(Date:3/28/2017)... CT (PRWEB) , ... March 28, 2017 , ... ... devices, announces today that the University of Pittsburgh Medical Center (UPMC) will acquire ... and Western Pennsylvania. , The program, developed in association with efforts by the ...
(Date:3/28/2017)... ... March 28, 2017 , ... Calibration, qualification, and the ... results and maintaining GMP and USP compliance. In a new webinar from METTLER ... requirements " these requirements are explained. The challenge is to determine how ...
(Date:3/28/2017)... ... March 28, 2017 , ... With less than 10,000 dermatologists in the ... care can be limited while the desire to conquer breakouts and eliminate skincare stress ... for every customer online, today released its inaugural survey on the State of Acne ...
(Date:3/28/2017)... ... March 28, 2017 , ... Columbus OH. Dr. Justin Harper, Founder of Juvly ... professionals in the country to sit on the 2017 National Advisory Board for Allergan’s ... years Dr. Harper helped propel the clinic from a small start-up to number 78 ...
(Date:3/28/2017)... PA (PRWEB) , ... March 28, 2017 , ... Public ... and across a variety of business channels. , While many results are clear, ... any public relations program. , When it comes to measurement, firms should always ...
Breaking Medicine News(10 mins):